General Manager, Decipher Urologic Cancers · VERACYTE, INC. (VCYT)

Tina Nova

FY2022 is the first fiscal year CompBrief holds for Tina Nova as a named executive officer of VERACYTE; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$4,598,529

Salary $500,000Stock awards $2,206,990

2nd of 5 named executive officers at Veracyte by FY2022 total.

5 named officers on file for VERACYTE, FY2022

Tina Nova’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 3 equity grants, each cited to its filing
  • VCYT’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how VERACYTE’s whole pay program stands against its peers

  • VERACYTE’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VCYT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 27, 2023 (DEF 14A).

Free

Get Tina Nova’s full pay file as a PDF — free

More than this page: up to 10 years of Tina’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Tina Nova compensation by year

VERACYTE Summary Compensation Table · the one fiscal year held
In US dollars, as VERACYTE reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022
Salary$500,000
Bonus$0
Stock awards$2,206,990
Option awards$1,476,039
Non-equity incentive$412,500
Pension and deferred compensation$0
All other$3,000
Total$4,598,529

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: VERACYTE, INC. DEF 14A filed April 27, 2023, accession 0001384101-23-000055, and prior-year filings. Open the filing on EDGAR.

How this page was built: the VERACYTE, INC. filed document, accession 0001384101-23-000055. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2023.

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU56,546$1,341,837—
PSU28,273$670,918—
Option37,773—$26.02

Per the Outstanding Equity Awards at Fiscal Year-End table in VERACYTE, INC.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

VERACYTE’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Marc StapleyChief Executive Officer$4,935,422
Tina Nova · this pageGeneral Manager, Decipher Urologic Cancers$4,598,529
Giulia KennedyFormer Global Chief Scientific and Chief Medical Officer$4,533,563
Rebecca ChambersChief Financial Officer$3,322,756
Annie McGuireGeneral Counsel and Chief People Officer$2,447,055

Board service

VERACYTE board · FY2021
Director compensation in US dollars, as VERACYTE reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2021$4,583$0——$4,583

Each year as the company reported it in VERACYTE's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: VERACYTE pays directors a $50,000 cash retainer and $250,000 in equity. As stated in VERACYTE's FY2025 proxy.

The full VERACYTE compensation record

free company brief

This page is one person within VERACYTE's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are VERACYTE's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Tina Nova's compensation dossier · One-time report. No refunds.